{
  "protocolSection": {
    "identificationModule": null,
    "descriptionModule": null,
    "conditionsModule": null,
    "designModule": null,
    "armsInterventionsModule": null,
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Treatment-emergent adverse events (TEAEs)",
          "description": "Safety was assessed by monitoring of treatment-emergent adverse events, including injection-site reactions, laboratory and vital sign assessments. TEAEs were recorded based on patient reports using Medical Dictionary for Regulatory Activities version 22.0 by system organ class and preferred term and summarized according to severity, seriousness, and relationship to the study drug and treatment discontinuation.",
          "timeFrame": "52-week treatment period plus 225-day follow-up period (approximately 84 weeks total)"
        },
        {
          "measure": "Injection-site reactions",
          "description": "Injection sites were monitored for reactions (erythema, induration, ecchymosis, and pain) and classified according to severity (none; mild, ≤ 5 to 50 mm, moderate, > 50 to ≤ 100 mm; severe, > 100 mm) with pain graded on a 5-point scale (painless, 0 to extreme, 4).",
          "timeFrame": "52-week treatment period"
        },
        {
          "measure": "Anti-drug antibody (ADA) development",
          "description": "Immunogenicity was assessed by measuring the incidence of anti-drug antibody development and production of neutralizing antibodies in patients who received fremanezumab.",
          "timeFrame": "52-week treatment period plus 225-day follow-up period (approximately 84 weeks total)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change from baseline in average monthly migraine days",
          "description": "The average monthly migraine days were calculated based on patient-reported data from electronic headache diaries. Headache-related data were normalized to 28 days of data when the number of evaluation days of the electronic headache diary in each month was 10 days or more.",
          "timeFrame": "Baseline, Month 1, Month 2, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "Change from baseline in average monthly headache days of at least moderate severity",
          "description": "The average monthly headache days of at least moderate severity were calculated based on patient-reported data from electronic headache diaries. Headache-related data were normalized to 28 days of data when the number of evaluation days of the electronic headache diary in each month was 10 days or more.",
          "timeFrame": "Baseline, Month 1, Month 2, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "Change from baseline in average monthly headache days of any severity",
          "description": "The average monthly headache days of any severity were calculated based on patient-reported data from electronic headache diaries.",
          "timeFrame": "Baseline, Month 1, Month 2, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "Change from baseline in average monthly days with use of any acute headache medications",
          "description": "The average monthly days with use of any acute headache medications were calculated based on patient-reported data from electronic headache diaries.",
          "timeFrame": "Baseline, Month 1, Month 2, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "≥50% responder rate for monthly migraine days",
          "description": "The percentage of patients with a ≥50% reduction in monthly migraine days from baseline at each month.",
          "timeFrame": "Month 1, Month 2, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "≥50% responder rate for monthly headache days of at least moderate severity",
          "description": "The percentage of patients with a ≥50% reduction in monthly headache days of at least moderate severity from baseline at each month.",
          "timeFrame": "Month 1, Month 2, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "Change from baseline in average monthly days with nausea or vomiting",
          "description": "The average monthly days with nausea or vomiting were calculated based on patient-reported data from electronic headache diaries.",
          "timeFrame": "Baseline, Month 1, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "Change from baseline in average monthly days with photophobia and phonophobia",
          "description": "The average monthly days with photophobia and phonophobia were calculated based on patient-reported data from electronic headache diaries.",
          "timeFrame": "Baseline, Month 1, Month 3, Month 6, and Month 12"
        },
        {
          "measure": "Change from baseline in 6-Item Headache Impact Test (HIT-6) score in patients with chronic migraine",
          "description": "The HIT-6 is a reliable and validated tool to assess headache-related disability, with higher scores indicating more severe impact. Scores range from 36 to 78.",
          "timeFrame": "Baseline and Month 12"
        },
        {
          "measure": "Change from baseline in Migraine Disability Assessment (MIDAS) score in patients with episodic migraine",
          "description": "The MIDAS is a reliable and validated tool to assess migraine-related disability, with higher scores indicating more severe disability.",
          "timeFrame": "Baseline and Month 12"
        },
        {
          "measure": "Number of patients who discontinued concomitant preventive migraine medications during the treatment period",
          "description": "The number of patients who discontinued concomitant preventive migraine medications during the 52-week treatment period.",
          "timeFrame": "52-week treatment period"
        }
      ]
    },
    "eligibilityModule": null
  }
}